An FDA advisory panel is considering two drugmakers to make the first respiratory syncytial virus (RSV) vaccine.
Feb. 28, 2023 -- An FDA advisory panel is considering two drugmakers to make the first respiratory syncytial virus vaccine.reported. Pfizer and GSK seek to lead the market that could be worth between $5 billion and $10 billion.
“The FDA is scheduled to decide on approval of the vaccines for people aged 60 and above by May, and typically follows the recommendations of its independent panel of experts,” Reuters wrote.Merck, Moderna and Johnson & Johnson are working on their own RSV vaccines. Last year, studies showed Pfizer and GSK doses prevented diseases RSV causes. GSK's vaccine was 82.6% effective in preventing lower respiratory tract disease in people over 60, and 94.1% effective in preventing severe disease. Pfizer's was 66.7% effective in preventing RSV-related lower respiratory tract illness with over two symptoms, and 85.7% effective against those with more than three.
"RSV is the last of the great big respiratory viruses that afflict our population on an annual basis," said William Schaffner, MD, an infectious disease expert at Vanderbilt University Medical Center.says adults at highest risk for severe RSV infection include those over 65; adults with chronic heart or lung disease; and those with weakened immune systems.
Adults typically have mild cold-like symptoms with RSV, but lung infections or pneumonia are possible, the CDC says. RSV can sometimes also lead to worsening of serious conditions such as asthma, chronic obstructive pulmonary disease, and congestive heart failure.Show SourcesCDC: “Respiratory Syncytial Virus Infection : Older Adults”
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer, GSK face FDA panel review in race for RSV vaccinesThe frontrunners in a crowded race to develop the first respiratory syncytial virus (RSV) vaccine - Pfizer Inc and GSK - will face scrutiny from a panel of experts to the U.S. Food and Drug Administration this week.
Baca lebih lajut »
FDA panel narrowly backs Pfizer's RSV vaccine for older adultsFederal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against...
Baca lebih lajut »
U.S. FDA panel votes for Pfizer's RSV vaccineA panel of outside advisers to the U.S. Food and Drug Administration (FDA) on Tuesday recommended Pfizer Inc's respiratory syncytial virus (RSV) vaccine, paving the way for one of the first approved RSV shots in the United States for older adults.
Baca lebih lajut »
FDA warns of Guillain-Barre syndrome as possible risk of Pfizer’s RSV vaccineGuillain-Barre syndrome, or inflammatory neuropathy, is a disorder in which the body’s immune system mistakenly attacks the nerves.
Baca lebih lajut »
FDA advisors recommend Pfizer RSV vaccine for older adults, despite possible Guillain-Barre risks
Baca lebih lajut »
Paving the way for the world's first RSV vaccine, FDA advisers recommend shot from PfizerBREAKING: FDA advisers recommend that the agency approve the country’s first RSV vaccine for older people, a shot from Pfizer for adults ages 60 and up.
Baca lebih lajut »